首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles
【24h】

Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles

机译:一系列新型光学活性6-硝基-2,3-二氢咪唑并[2,1-b]恶唑类化合物的合成及抗结核活性

获取原文
获取原文并翻译 | 示例
       

摘要

In an effort to develop potent new antituberculosis agents that would be effective against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, we prepared a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles substituted at the 2-position with various phenoxymethyl groups and a methyl group and investigated the in vitro and in vivo activity of these compounds. Several of these derivatives showed potent in vitro and in vivo activity, and compound 19 (OPC-67683) in particular displayed excellent in vitro activity against both drug-susceptible and drug-resistant strains of M. tuberculosis H(37)Rv (MIC = 0.006 mu g/mL) and dose-dependent and significant in vivo efficacy at lower oral doses than rifampicin in mouse models infected with M. tuberculosis Kurono. The synthesis and structure-activity relationships of these new compounds are presented.
机译:为了开发有效的新型抗结核药,该药对结核分枝杆菌的药敏和耐药菌株均有效,我们制备了一系列新型的旋光性6-硝基-2,3-二氢咪唑[2,1-b ]恶唑在2-位被各种苯氧基甲基和甲基取代,并研究了这些化合物的体外和体内活性。这些衍生物中的几种显示出有效的体外和体内活性,尤其是化合物19(OPC-67683)对结核分枝杆菌H(37)Rv(MIC =在感染了结核分枝杆菌Kurono的小鼠模型中,口服剂量比利福平更低,剂量依赖性和显着的体内功效,且口服剂量低于利福平。介绍了这些新化合物的合成和构效关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号